Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure

PLoS ONE

Volumn 2, Issue 1, 2007, Pages

  Sendi, Pedram ^a,b   Günthard, Huldrych F ^c   Simcock, Mathew ^a,b   Ledergerber, Bruno ^c   Schüpbach, Jörg ^d   Battegay, Manuel ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL RESISTANCE; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG TREATMENT FAILURE; GENOTYPE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; OUTCOME ASSESSMENT; PROBABILITY; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; SOCIAL ASPECT; VIRUS LOAD; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG EFFECT; ECONOMICS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; QUALITY OF LIFE; THEORETICAL MODEL; TREATMENT FAILURE;

ANTI-HIV AGENTS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; GENOTYPE; HEALTH CARE COSTS; HIV INFECTIONS; HIV-1; HUMANS; LIFE EXPECTANCY; MODELS, THEORETICAL; QUALITY OF LIFE; TREATMENT FAILURE;

EID: 41349084678     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0000173     Document Type: Article

References (53)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338(13): 853-860.
2. Egger M, Hirschel B, Francioli P, et al. (1997) Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 315(7117): 1194-1199.
3. Sterne JA, Hernan MA, Ledergerber B, et al. (2005) Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 366(9483): 378-384.
4. Yeni PG, Hammer SM, Hirsch MS, et al. (2004) Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 292(2): 251-265.
5. Grant RM, Hecht FM, Warmerdam M, et al. (2002) Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288(2): 181-188.
6. Hermankova M, Ray SC, Ruff C, et al. (2001) HIV-1 drug resistance profiles in children and adults with viral load of ,50 copies/ml receiving combination therapy. JAMA 286(2): 196-207.
7. Ochoa DE, Arnedo M, Xercavins M, et al. (2005) Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir. AIDS 19(13): 1385-1391.
8. Ena J, Ruiz de Apodaca RF, Amador C, Benito C, Pasquau F (2006) Net benefits of resistance testing directed therapy compared with standard of care in HIV-infected patients with virological failure: A meta-analysis. Enferm Infecc Microbiol Clin 24(4): 232-237.
9. Hirsch HH, Drechsler H, Holbro A, et al. (2005) Genotypic and phenotypic resistance testing of HIV-1 in routine clinical care. Eur J Clin Microbiol Infect Dis 24(11): 733-738.
10. Torre D, Tambini R (2002) Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study. HIV Clin Trials 3(1): 1-8.
11. Clevenbergh P, Durant J, Halfon P, et al. (2000) Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up. Antivir Ther 5(1): 65-70.
12. Vandamme AM, Sonnerborg A, Ait-Khaled M, et al. (2004) Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 9(6): 829-848.
13. Hirsch MS, Brun-Vezinet F, Clotet B, et al. (2003) Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 37(1): 113-128.
14. Hirsch MS, Brun-Vezinet F, Clotet B, et al. (2003) Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel. Top HIV Med 11(4): 150-154.
15. Simcock M, Sendi P, Ledergerber B, et al. (2006) A longitudinal analysis of health care costs after treatment optimisation following genotypic antiretroviral resistance testing: does resistance testing pay off? Antivir Ther 11: 305-314.
16. Sax PE, Islam R, Walensky RP, et al. (2005) Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 41(9): 1316-1323.
17. Weinstein MC, Goldie SJ, Losina E, et al. (2001) Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness. Ann Intern Med 134(6): 440-450.
18. Corzillius M, Muhlberger N, Sroczynski G, Jaeger H, Wasem J, Siebert U (2004) Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV. Antivir Ther 9(1): 27-36.
19. Chaix C, Grenier-Sennelier C, Clevenbergh P, et al. (2000) Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study. J Acquir Immune Defic Syndr 24(3): 227-231.
20. Ledergerber B, von Overbeck J, Egger M, Luthy R (1994) The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Praventivmed 39(6): 387-394.
21. Haupts S, Ledergerber B, Boni J, et al. (2003) Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Antivir Ther 8(5): 443-454.
22. Krahn M, Gafni A (1993) Discounting in the economic evaluation of health care interventions. Med Care 31(5): 403-418.
23. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW (1997) Methods for the economic evaluation of health care programmes. 2nd edition ed. Oxford: Oxford University Press.
24. Briggs A, Sculpher M (1998) An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 13(4): 397-409.
25. Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13(4): 322-338.
26. Durant J, Clevenbergh P, Halfon P, et al. (1999) Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353(9171): 2195-2199.
27. Panidou ET, Trikalinos TA, Ioannidis JP (2004) Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis. AIDS 18(16): 2153-2161.
28. McCarthy BD, Wong JB, Munoz A, Sonnenberg FA (1993) Who should be screened for HIV infection? A cost-effectiveness analysis. Arch Intern Med 153(9): 1107-1116.
29. Sendi PP, Bucher HC, Harr T, et al. (1999) Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. AIDS 13(9): 1115-1122.
30. Sendi PP, Bucher HC, Craig BA, Pfluger D, Battegay M (1999) Estimating AIDS-free survival in a severely immunosuppressed asymptomatic HIV-infected population in the era of antiretroviral triple combination therapy. Swiss HIV Cohort Study. J Acquir Immune Defic Syndr Hum Retrovirol 20(4): 376-381.
31. Tengs TO, Lin TH (2002) A meta-analysis of utility estimates for HIV/ AIDS. Med Decis Making 22(6): 475-481.
32. Zinkernagel C, Ledergerber B, Battegay M, et al. (1999) Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. AIDS 13(12): 1587-1589.
33. Mrus JM, Yi MS, Freedberg KA, et al. (2003) Utilities derived from visual analog scale scores in patients with HIV/AIDS. Med Decis Making 23(5): 414-421.
34. Krol M, Brouwer W, Sendi P (2006) Productivity costs in health-state valuations: does explicit instruction matter? Pharmacoeconomics 24(4): 401-414.
35. Sendi P, Brouwer WB (2005) Is silence golden? A test of the incorporation of the effects of ill-health on income and leisure in health state valuations. Health Econ 14(6): 643-647.
36. Meltzer D, Johannesson M (1999) Inconsistencies in the "societal perspective" on costs of the Panel on Cost-Effectiveness in Health and Medicine. Med Decis Making 19(4): 371-377.
37. Sendi P, Schellenberg F, Ungsedhapand C, et al. (2004) Productivity costs and determinants of productivity in HIV-infected patients. Clin Ther 26(5): 791-800.
38. Johannesson M, Meltzer D (1998) Some reflections on cost-effectiveness analysis. Health Econ 7(1): 1-7.
39. Johannesson M, Meltzer D, O'Conor RM (1997) Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension. Med Decis Making 17(4): 382-389.
40. Claxton K, Sculpher M, McCabe C, et al. (2005) Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 14(4): 339-347.
41. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ (1985) Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 5(2): 157-177.
42. Sendi PP, Craig BA, Meier G, et al. (1999) Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy.The Swiss HIV Cohort Study. J Antimicrob Chemother 44(6): 811-817.
43. Briggs AH (1999) A Bayesian approach to stochastic cost-effectiveness analysis. Health Econ 8(3): 257-261.
44. Briggs AH, Goeree R, Blackhouse G, O'Brien BJ (2002) Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 22(4): 290-308.
45. Briggs AH, Ades AE, Price MJ (2003) Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. Med Decis Making 23(4): 341-350.
46. van Hout BA, Al MJ, Gordon GS, Rutten FF (1994) Costs, effects and C/ E-ratios alongside a clinical trial. Health Econ 3(5): 309-319.
47. Hunink MG, Bult JR, de Vries J, Weinstein MC (1998) Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method. Med Decis Making 18(3): 337-346.
48. Wright JC, Weinstein MC (1998) Gains in life expectancy from medical interventions-standardizing data on outcomes. N Engl J Med 339(6): 380-386.
49. Sanders GD, Hlatky MA, Owens DK (2005) Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 353(14): 1471-1480.
50. Kaiser C, Brunner-La Rocca HP, Buser PT, et al. (2005) Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 366(9489): 921-929.
51. Sendi PP, Craig BA, Pfluger D, Gafni A, Bucher HC (1999) Systematic validation of disease models for pharmacoeconomic evaluations. Swiss HIV Cohort Study. J Eval Clin Pract 5(3): 283-295.
52. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS (2003) Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.35×610(9) cells/L. Ann Intern Med 139(10): 810-816.
53. Jiang H, Deeks SG, Kuritzkes DR, et al. (2003) Assessing resistance costs of antiretroviral therapies via measures of future drug options. J Infect Dis 188(7): 1001-1008.